- Home
- ZBAI vs SNOA Comparison
ZBAI vs SNOA Comparison
Compare ZBAI & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- SNOA
- Stock Information
- Founded
- ZBAI 2015
- SNOA 1999
- Country
- ZBAI United States
- SNOA United States
- Employees
- ZBAI N/A
- SNOA N/A
- Industry
- ZBAI Professional Services
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- SNOA Health Care
- Exchange
- ZBAI Nasdaq
- SNOA Nasdaq
- Market Cap
- ZBAI 6.5M
- SNOA 7.5M
- IPO Year
- ZBAI N/A
- SNOA 2007
- Fundamental
- Price
- ZBAI $6.68
- SNOA $4.57
- Analyst Decision
- ZBAI
- SNOA
- Analyst Count
- ZBAI 0
- SNOA 0
- Target Price
- ZBAI N/A
- SNOA N/A
- AVG Volume (30 Days)
- ZBAI 27.0K
- SNOA 3.9M
- Earning Date
- ZBAI 06-06-2025
- SNOA 11-06-2025
- Dividend Yield
- ZBAI N/A
- SNOA N/A
- EPS Growth
- ZBAI N/A
- SNOA N/A
- EPS
- ZBAI N/A
- SNOA N/A
- Revenue
- ZBAI $720,000.00
- SNOA $14,912,000.00
- Revenue This Year
- ZBAI N/A
- SNOA $23.00
- Revenue Next Year
- ZBAI N/A
- SNOA $24.59
- P/E Ratio
- ZBAI N/A
- SNOA N/A
- Revenue Growth
- ZBAI 44.00
- SNOA 17.43
- 52 Week Low
- ZBAI $4.83
- SNOA $1.75
- 52 Week High
- ZBAI $45.00
- SNOA $6.92
- Technical
- Relative Strength Index (RSI)
- ZBAI 55.05
- SNOA 55.92
- Support Level
- ZBAI $5.65
- SNOA $4.45
- Resistance Level
- ZBAI $6.43
- SNOA $4.74
- Average True Range (ATR)
- ZBAI 0.60
- SNOA 0.27
- MACD
- ZBAI 0.19
- SNOA -0.07
- Stochastic Oscillator
- ZBAI 73.83
- SNOA 16.98
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.